shutterstock_17556916_-ouh_desire

Ouh Desire / Shutterstock.com

30 September 2019BiotechnologyRichard Wells and Stephanie Pilkington

Dosage patents: Down the hatch

The Supreme Court judgment on March 27, 2019 in Actavis v ICOS UK concerned ICOS’s EP (UK) 1 173 181, exclusively licensed to Eli Lilly, and found it invalid for lack of inventive step in the face of Actavis’, and others’, revocation challenge.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

China’s new policies on foreign investment in healthcare and biotech

Startup CFO’s betrayal is a lesson in preparing for the worst

Sanofi subsidiary fends off $450m trade secrets case

Pfizer infringed haemophilia therapy patent, says court

Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar

Big Pharma counsel embrace AI but data and legal risks loom

10x Genomics counsel: ‘Winning cases is a top priority’

HR, lobbying and business strategy…all in a day’s work for today’s counsel